Resources from the same session
161O - VIOLETTE: Randomised Phase 2 Study of Olaparib (ola) + Ceralasertib (cer) or Adavosertib (ada) vs Ola Alone in Patients (pts) With Metastatic Triple-Negative Breast Cancer (mTNBC)
Presenter: Andrew Tutt
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
58O - Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
Presenter: Frederik Marmé
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 58O
Presenter: Barbara Pistilli
Session: Proffered Paper session 2
Resources:
Slides
Webcast
LBA1 - Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial
Presenter: Maria Fernanda Mosele
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1
Presenter: Peter A. Fasching
Session: Proffered Paper session 2
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session 2
Resources:
Webcast